EA202092125A1 - Антитела против рецептора фолата 1 и их применения - Google Patents
Антитела против рецептора фолата 1 и их примененияInfo
- Publication number
- EA202092125A1 EA202092125A1 EA202092125A EA202092125A EA202092125A1 EA 202092125 A1 EA202092125 A1 EA 202092125A1 EA 202092125 A EA202092125 A EA 202092125A EA 202092125 A EA202092125 A EA 202092125A EA 202092125 A1 EA202092125 A1 EA 202092125A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- receptor
- antibodies against
- application
- against folate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642213P | 2018-03-13 | 2018-03-13 | |
| PCT/US2019/021084 WO2019177854A1 (en) | 2018-03-13 | 2019-03-07 | Anti-folate receptor 1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092125A1 true EA202092125A1 (ru) | 2020-12-15 |
Family
ID=67906883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092125A EA202092125A1 (ru) | 2018-03-13 | 2019-03-07 | Антитела против рецептора фолата 1 и их применения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11873335B2 (enExample) |
| EP (1) | EP3765521A4 (enExample) |
| JP (2) | JP7433236B2 (enExample) |
| KR (1) | KR102808710B1 (enExample) |
| CN (1) | CN111954681B (enExample) |
| AU (1) | AU2019236091B2 (enExample) |
| BR (1) | BR112020016469A2 (enExample) |
| CA (1) | CA3091683A1 (enExample) |
| EA (1) | EA202092125A1 (enExample) |
| IL (1) | IL276949A (enExample) |
| MX (1) | MX2020009522A (enExample) |
| SG (1) | SG11202007494TA (enExample) |
| WO (1) | WO2019177854A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| JP7900284B2 (ja) * | 2019-12-17 | 2026-08-04 | フェインズ セラピューティクス，インコーポレーテッド | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 |
| TW202233684A (zh) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| WO2022217022A1 (en) * | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| WO2025140416A1 (zh) * | 2023-12-28 | 2025-07-03 | 上海宏成药业有限公司 | 抗folr1特异性抗体的发明及应用 |
| CN118344485B (zh) * | 2024-06-18 | 2024-10-15 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
| FR2929946B1 (fr) | 2008-04-11 | 2010-05-28 | Pf Medicament | Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| CN105777907B (zh) * | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| KR20140032944A (ko) | 2010-10-20 | 2014-03-17 | 모르포테크, 인크. | 항폴레이트 수용체 알파 항체 당형태 |
| SG189957A1 (en) | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| ES2661466T3 (es) | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1 |
| CN107011439B (zh) | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
| JP6122948B2 (ja) | 2012-05-15 | 2017-04-26 | モルフォテック， インコーポレイテッド | 胃癌の治療のための方法 |
| SG11201500938XA (en) * | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| CN104884617B (zh) * | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | 抗folr1抗体 |
| US9522196B2 (en) | 2012-12-25 | 2016-12-20 | Kagoshima University | Antibody recognizing folate receptors α and β |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP2997044A4 (en) | 2013-05-14 | 2017-03-22 | ImmunoGen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| BR112015031950A2 (pt) | 2013-06-20 | 2017-07-25 | Morphotek Inc | métodos para tratamento de câncer de ovário |
| NZ717140A (en) * | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| JP6463744B2 (ja) | 2013-10-08 | 2019-02-06 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| EP3077522A1 (en) | 2013-12-04 | 2016-10-12 | Immunogen, Inc. | Compositions and methods for antibody production |
| KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
| SG11201701565PA (en) | 2014-09-03 | 2017-03-30 | Immunogen Inc | Conjugates comprising cell-binding agents and cytotoxic agents |
| SG11201704056XA (en) * | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CA2983126A1 (en) | 2015-04-17 | 2016-10-20 | Morphotek, Inc. | Methods for treating lung cancer |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| US20190233512A1 (en) | 2016-10-12 | 2019-08-01 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| BR112019023909A8 (pt) | 2017-05-16 | 2023-04-11 | Immunogen Inc | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab |
-
2019
- 2019-03-07 EP EP19767635.6A patent/EP3765521A4/en active Pending
- 2019-03-07 MX MX2020009522A patent/MX2020009522A/es unknown
- 2019-03-07 AU AU2019236091A patent/AU2019236091B2/en active Active
- 2019-03-07 KR KR1020207028499A patent/KR102808710B1/ko active Active
- 2019-03-07 JP JP2020548760A patent/JP7433236B2/ja active Active
- 2019-03-07 SG SG11202007494TA patent/SG11202007494TA/en unknown
- 2019-03-07 BR BR112020016469-0A patent/BR112020016469A2/pt not_active IP Right Cessation
- 2019-03-07 CN CN201980019246.4A patent/CN111954681B/zh active Active
- 2019-03-07 EA EA202092125A patent/EA202092125A1/ru unknown
- 2019-03-07 CA CA3091683A patent/CA3091683A1/en active Pending
- 2019-03-07 WO PCT/US2019/021084 patent/WO2019177854A1/en not_active Ceased
- 2019-03-07 US US15/733,541 patent/US11873335B2/en active Active
-
2020
- 2020-08-26 IL IL276949A patent/IL276949A/en unknown
-
2024
- 2024-02-06 JP JP2024016283A patent/JP2024056787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024056787A (ja) | 2024-04-23 |
| CN115925952A (zh) | 2023-04-07 |
| JP2021517459A (ja) | 2021-07-26 |
| SG11202007494TA (en) | 2020-09-29 |
| AU2019236091A1 (en) | 2020-09-03 |
| EP3765521A1 (en) | 2021-01-20 |
| US20210002363A1 (en) | 2021-01-07 |
| CN111954681A (zh) | 2020-11-17 |
| AU2019236091B2 (en) | 2025-06-05 |
| BR112020016469A2 (pt) | 2020-12-15 |
| KR102808710B1 (ko) | 2025-05-15 |
| EP3765521A4 (en) | 2022-03-23 |
| WO2019177854A1 (en) | 2019-09-19 |
| CN111954681B (zh) | 2022-12-06 |
| JP7433236B2 (ja) | 2024-02-19 |
| KR20200132900A (ko) | 2020-11-25 |
| US11873335B2 (en) | 2024-01-16 |
| CA3091683A1 (en) | 2019-09-19 |
| MX2020009522A (es) | 2020-10-22 |
| IL276949A (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| EA201791590A1 (ru) | Антитела к tau и их применение | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| MY200162A (en) | Anti-gitr antibodies and uses thereof | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202092518A1 (ru) | Композиции и способы лечения рака | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения | |
| ZA202110285B (en) | Antibodies and methods of use | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения |